

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

10 March 2026 | News

Device is designed for complex percutaneous coronary interventions (PCI)



Abbott, the global healthcare company, has announced the launch of XIENCE Skypoint in India. This is Abbott's most advanced generation stent within the globally trusted XIENCE™ family of everolimus (drug)-eluting coronary stents (DES). The stent is designed to be more flexible, easier to guide through the heart's arteries, including large vessels, and better suited for treating complex heart blockages.

Tushar Sharma, general manager for Abbott's vascular business in India and South Asia said, "The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India. Many patients today develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks. This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages. XIENCE Skypoint brings improvements with precision and strengthens our commitment to providing advanced heart treatments across the country."

Abbott has introduced newer generations of XIENCE, with the goal of providing physicians with access to the latest DES technology. With this launch, XIENCE Skypoint brings the broadest size matrix ever offered by the XIENCE family, supporting the treatment of long lesions while helping reduce the number of stents required per procedure.

The platform also introduces 4.5 mm and 5.0 mm diameters, making it the only DES indicated for vessels up to 5.25 mm. This is especially important because real-world patients at times have bigger or more varied artery sizes that need the right fit.